Model explores how statins alter multiple sclerosis outcomes

(HealthDay)—Simvastatin's beneficial effects on clinical outcomes and brain atrophy in patients with multiple sclerosis (MS) are largely independent of cholesterol levels, according to a post hoc study published in the May 28 issue of the Proceedings of the National Academy of Sciences.

* This article was originally published here